Orgametril®

Pharmacodynamics and pharmacokinetics

Orgametril is a synthetic progestogen intended for internal use. Its active component is characterized by pharmacological properties similar to natural progesterone . When treated with this drug, a pronounced progestogenic effect on the endometrium is manifested. Continuous use helps suppress ovulation and menstruation. Therefore, the drug is prescribed when it is necessary to demonstrate its pronounced progestogenic effect.

Inside the body , linestrenol undergoes rapid absorption and is converted into active norethisterone . Metabolism occurs in the liver. The maximum concentration of norethisterone in the blood plasma is detected 2-4 hours after taking the drug. The substance is eliminated through the kidneys and intestines.

Pharmacological properties of the drug Orgametril

Pharmacodynamics . Linestrenol has a pronounced progestogenic effect on the endometrium. Long-term use of the drug leads to inhibition of ovulation and an increase in the onset of menstruation. Orgametril can be used for conditions whose treatment requires the administration of agents with progestogenic properties. Pharmacokinetics. When taken orally, linestrenol is quickly absorbed in the digestive tract and in the liver undergoes subsequent conversion into the pharmacologically active norethisterone, which has a biological effect. The maximum level of norethisterone in the blood plasma is observed within 2–4 hours after oral administration of linestrenol. Linestrenol and its metabolites are excreted from the body primarily through urine, and to a lesser extent through feces.

Indications for use

The medicine is recommended for use when:

• dysfunctional uterine bleeding;
• amenorrhea;
• oligomenorrhea;
• dysmenorrhea;
• premenstrual syndrome;
• endometriosis;
• endometrial carcinoma;
• benign breast tumor;
• delay of normal menstruation;
• hormone replacement therapy with estrogen - in complex treatment.

Side effects

When treated with Orgametril, various undesirable effects may develop, for example: nausea, weight gain, development of heavy bleeding and spotting.

In rare cases, the following may occur: headache, nervousness , dizziness, migraine, depression, jaundice, chest pain, changes in liver function. A decrease in glucose tolerance is also noted, acne, chloasma , rashes and skin itching , and hirsutism appear. After stopping treatment, swelling and amenorrhea may develop .

Special instructions for the use of the drug Orgametril

Patients with circulatory disorders (currently or in history), as well as with some forms of severe depression, should be under constant medical supervision due to the possible exacerbation of these conditions. During long-term treatment with progestogens, periodic medical examination is recommended. Sometimes taking the drug may be accompanied by changes in liver function, carbohydrate metabolism and blood coagulation. If the functional parameters of these systems deteriorate, treatment should be discontinued. LDL levels may increase and HDL levels may decrease. Women prone to chloasma should avoid exposure to direct sunlight. If pregnancy occurs and during breastfeeding, the drug should be discontinued. Linestrenol has a slight androgenic effect and some patients may experience mild signs of virilism (acne and hirsutism).

Instructions for use of Orgametril (Method and dosage)

This drug is intended for oral administration with liquid. If you miss another pill, you must take it immediately, unless the dose is delayed for more than 24 hours.

It should be noted that the first day of the cycle is the beginning of menstrual bleeding.

For polymenoria, a daily dosage of 5 mg or one tablet is prescribed, which should be taken 14-25 days during the menstrual cycle.

Treatment of menorrhagia and metrorrhagia requires taking two tablets per day for 10 days. As a rule, the bleeding stops after a few days. It is recommended to repeat the therapeutic course for the next three menstrual cycles at a dosage of 14-25 days. When treatment is ineffective, additional examination is prescribed and appropriate therapy is selected.

In any case, the drug is prescribed by the attending physician, who determines the dosage and treatment regimen. Diagnostics are carried out regularly to confirm the effectiveness of treatment. The use of the drug without a prescription from a specialist is contraindicated.

Use of the drug Orgametril

Orgametril tablets are taken orally with a small amount of liquid. For polymenorrhea, 1 tablet per day is prescribed from the 14th to the 25th day of the cycle inclusive. For meno- and metrorrhagia - 2 tablets per day for 10 days. Bleeding usually stops within a few days of starting treatment. Over the next 3 cycles, treatment must be repeated, taking 1 tablet per day from the 14th to the 25th day of each cycle. If the treatment is ineffective, further diagnosis is necessary to determine the cause of the disorder. In case of primary or secondary amenorrhea and oligomenorrhea, at the initial stage of treatment it is necessary to include estrogens in the treatment regimen (for example, ethinyl estradiol at a dose of 0.02–0.005 mg/day) for 25 days. At the same time, from the 14th to the 25th day of the cycle, Orgametril is used, 1 tablet per day. As a rule, a menstrual-like reaction occurs on the 3rd day after discontinuation of the drug. Treatment begins again (2nd cycle) from the 5th day of a menstrual-like reaction, while the estrogen drug is prescribed from the 5th to 25th day of the cycle, and Orgametril - from the 14th to 25th day of the cycle, 1 tablet per day. The course of treatment should be repeated at least once. For premenstrual syndrome - 1 tablet from the 14th to the 25th day of the cycle. For endometriosis - 1-2 tablets per day for 6 months or more. For benign tumors of the mammary glands - 1 tablet daily from the 14th to the 25th day of the cycle for at least 3-4 months. To suppress menstruation, ovulation and relieve ovulatory pain and manifestations of dysmenorrhea, treatment should begin no later than the 5th day of the cycle, but it is preferable to start it from the 1st day of the cycle. The course of treatment when taking the drug daily should be continued continuously for many months. If, despite long-term treatment, so-called breakthrough bleeding occurs, the dose of the drug should be increased to 2-3 tablets over 3-5 days. Delay of normal menstruation - 1 tablet per day; the course of treatment should be carried out, if possible, 2 weeks before the expected start of menstruation. If the course of treatment is started less than 1 week before the expected start of menstruation, the dose should be 2-3 tablets per day. In this case, a delay of more than 1 week is undesirable. If treatment is started later, the risk of breakthrough bleeding increases. Thus, the course of treatment should not be started later than 3 days before the expected start of menstruation. As part of combination therapy with estrogens in the pre- and postmenopausal period to prevent endometrial hyperplasia - 1/2 -1 tablet per day for 12-15 days per month (for example, during the first 2 weeks of each calendar month). The estrogen drug can be taken continuously at the minimum effective dose.

Interaction

The simultaneous use of Orgametril with Rifamycin , Hydantoin derivatives, barbiturates, Carbamazepine and Aminogluthetimide , laxatives and Activated carbon significantly reduces its effect. However, Orgametril itself is capable of increasing the therapeutic, pharmacological or toxicological effects of Cyclosporine, Troleandomycin, Theophylline and beta-blockers.

Combination with macrolide antibiotics

It is noted that this drug reduces the properties of Insulin.

special instructions

The use of drugs with a high content of estrogen or progestogen can lead to the development of chloasma . Therefore, women who are predisposed to this need to protect themselves from exposure to UV rays on their skin.

Sex hormones influence specific laboratory parameters. As a result, it is possible that the level of LDL in the blood may increase or the level of HDL will decrease. There are some changes in liver function, carbohydrate metabolism and blood clotting.

During treatment, regular monitoring of the condition of patients with circulatory disorders is required, since hormonal substances can increase the risk of cardiovascular or cerebrovascular disorders.

You should also limit your intake of fats and carbohydrates, especially if women have a tendency to gain weight.

For patients with diabetes mellitus , monitoring of the glycemic profile is necessary in order to promptly adjust the insulin dose.

When dysfunctional uterine bleeding occurs in women of reproductive age, therapy is carried out only after therapeutic and diagnostic curettage of the uterine cavity.

If therapy is ineffective, manifested by recurrent bleeding and hyperplastic processes of the endometrium, an urgent clarification of the causes of bleeding is necessary.

Prolonged delay of menstruation during treatment requires examination to exclude the presence of an ectopic pregnancy.

It is known that Orgametril contains lactose . For this reason, the drug is contraindicated for use in patients suffering from hereditary disorders, such as galactose intolerance, lapp lactase deficiency, and glucose-galactose malabsorption.

ORGAMETRIL TAB. 5MG No. 30

Treatment should be interrupted if test results indicate liver dysfunction.

Chloasma is sometimes observed when taking medications containing estrogen and/or progestogen, especially in women with a history of chloasma during pregnancy. Women prone to chloasma should avoid exposing their skin to sunlight or artificial UV radiation.

Taking sex hormones may interfere with specific laboratory tests. In many patients, during treatment with Orgametril, the level of LDL in the blood may increase and the level of HDL will decrease. Changes in parameters of liver function, carbohydrate metabolism, and blood coagulation system are possible.

During long-term treatment, systematic medical examinations, monitoring of lipid and carbohydrate metabolism, bilirubin concentrations, transaminases, and coagulation systems are indicated. The frequency and nature of systematic medical examinations depend on the circumstances in each individual case and should be determined in accordance with clinical judgment, but at least once every 6 months.

Due to the effect of linestrenol on the level of sex hormone binding globulin, Orgametril may exhibit some androgenic activity. This may result in mild signs of virilization (mainly acne or seborrhea).

Epidemiological studies have revealed an association between the use of progestogen in combination with estrogens and an increased incidence of venous thromboembolism (deep vein thrombosis and pulmonary embolism). Although the clinical significance of these data for linestrenol without an estrogen component is unknown. In case of thrombosis, you should stop taking Orgametril. The need to discontinue Orgametril should also be considered in the event of prolonged immobilization due to surgery or illness. Women with a history of thromboembolic disease should be informed of the possibility of recurrence.

It is necessary to constantly monitor the condition of patients with circulatory disorders (as well as if there is a history of them), since when taking oral estrogen/progestin contraceptives, the risk of certain cardiovascular diseases or cerebrovascular conditions slightly increases.

While taking the drug Orgametril, it is recommended to limit the intake of fats and carbohydrates (which is especially important for women with initially increased body weight).

In case of diabetes mellitus, the glycemic profile should be monitored (increasing the insulin dose may be required).

If you are predisposed to arterial hypertension, it is necessary to control blood pressure (reduce fluid intake to 1.5-2 l/day).

In the case of dysfunctional uterine bleeding in women of reproductive age, it is recommended to begin therapy after therapeutic and diagnostic curettage of the uterus.

Ineffectiveness of therapy (recurrence of bleeding and hyperplastic processes of the endometrium) requires clarification of the causes of bleeding.

In case of prolonged delay of menstruation during therapy with Orgametril, ectopic pregnancy should be excluded.

Orgametril contains lactose as an excipient. Therefore, this drug should not be prescribed to patients with rare hereditary disorders such as galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption.

Reviews about Orgametril

A variety of drugs intended for the treatment of disorders of the reproductive and reproductive systems in women are especially actively discussed on the Internet. At the same time, reviews about Orgametril on forums devoted to this problem are in most cases positive.

Treatment with this drug is prescribed to women of different ages, setting the dosage and therapeutic regimen, depending on the type and complexity of the gynecological disorder. Of course, for its effectiveness to manifest itself, it is necessary to undergo long-term therapy, lasting several months. It is also possible to prescribe additional medications and procedures.

In addition, women say that the drug is not only highly effective, but also does not cause side effects. As you know, some patients are concerned about the problem of excess weight, but if the treatment is chosen correctly, then body weight does not increase.

Orgametril®

— Orgametril® contains lactose as an excipient. Therefore, this drug should not be taken by patients with rare hereditary conditions such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

- Treatment should be interrupted if test results indicate liver dysfunction.

— When taking medications containing estrogen and/or progestogen, especially in women with a history of chloasma during pregnancy, chloasma is sometimes observed. Women prone to chloasma should avoid exposing their skin to sunlight or artificial ultraviolet radiation.

- Taking sex hormones may affect specific laboratory tests. In many patients, during treatment with Orgametril®, there may be an increase in the level of low-density lipoproteins in the blood and a decrease in the level of high-density lipoproteins. Changes in parameters of liver function, carbohydrate metabolism, and blood coagulation system are possible.

— For long-term treatment, systematic medical examinations are indicated; control of lipid and carbohydrate metabolism, bilirubin concentrations, transaminases, coagulation system. The frequency and nature of systematic medical examinations depend on the circumstances in each individual case and should be determined in accordance with clinical judgment, but at least once every 6 months.

— Due to the effect of the drug Orgametril® on the level of sex hormone binding globulin (SHBG), Orgametril® may exhibit some androgenic activity. This may manifest itself in mild signs of virilization (mainly acne or seborrhea).

- Epidemiological studies have revealed an association between the use of progestogen in combination with estrogens and an increased incidence of venous thromboembolism (deep vein thrombosis and pulmonary embolism). Although the clinical significance of these data for linestrenol without an estrogen component is unknown, in the event of thrombosis, Orgametril® should be discontinued. The need to discontinue taking Orgametril should also be considered in case of prolonged immobilization due to surgery or illness. Women with a history of thromboembolic disease should be informed of the possibility of recurrence.

— Constant monitoring of the condition of patients with circulatory disorders (as well as if there is a history of them) is necessary, since when taking oral estrogen/progestin contraceptives, the risk of certain cardiovascular diseases or cerebrovascular conditions slightly increases.

— While taking Orgametril®, it is recommended to limit the intake of fats and carbohydrates (which is especially important for women with initially high body weight); in case of diabetes mellitus, the glycemic profile should be monitored (an increase in the insulin dose may be required).

— If you are predisposed to arterial hypertension, it is necessary to control blood pressure (reduce fluid intake to 1.5-2 l/day).

— In the case of dysfunctional uterine bleeding in women of reproductive age, it is recommended to begin therapy after therapeutic and diagnostic curettage of the uterus.

— Ineffectiveness of therapy (recurrences of bleeding and hyperplastic processes of the endometrium) requires clarification of the causes of bleeding.

- If there is a long delay in menstruation during therapy with Orgametril®, ectopic pregnancy should be excluded.

Organometril price, where to buy

The price of Orgametril in 5 mg tablets, for 30 pieces in a pack, varies between 1039-1100 rubles.

• Online pharmacies in RussiaRussia
• Online pharmacies in UkraineUkraine

LuxPharma* special offer

• Organametril tab.
  5 mg No. 30 1980 rub. order

ZdravCity

• Organometril tablets 5 mg 30 pcs.Organon

  RUB 2,755 order

Pharmacy Dialogue

• Organometril (5 mg tablet No. 30)Organon

  RUR 2,658 order

show more

Pharmacy24

• Organametril 5 mg No. 30 tablets N.V. Organon, Netherlands
  849 UAH. order